Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT

Summary

The goal of this phase I/II clinical trial is to test in high-risk acute myeloid leukemia (AML) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer is: • The efficacy and safety of chidamide maintenance therapy in reducing the recurrence rate and GVHD incidence in high-risk AML patients after allo-HSCT. Participants will take oral chidamide (Epidaza) until 180 days after allo-HSCT.

Timeline

Start

2022-12-22

Primary completion

2023-12-31

Completion

2026-12-31

Drugs

Indications